Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice

Cytotherapy

Volumn 13, Issue 6, 2011, Pages 695-704

  Godoy, Juliana A P ^a   Block, Daniel B ^a   Tollefsen, Douglas M ^b   Werneck, Claudio C ^a   Vicente, Cristina P ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone marrow cells; dermatan sulfate; infl ammation; restenosis; thrombosis

Indexed keywords

CD45 ANTIGEN; DERMATAN SULFATE; PADGEM PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY LESION; ARTICLE; BONE MARROW CELL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM LESION; LEUKOCYTE; LEUKOCYTE MIGRATION; MECHANICAL TORSION; MONONUCLEAR CELL; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOGENESIS; WOUND HEALING;

EID: 79959236950     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.548378     Document Type: Article

References (20)

1. Zhang QH, She MP. Biological behaviour and role of endothelial progenitor cells in vascular diseases. Chin Med J (Engl). 2007;120:2297-303.
2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-7. (Pubitemid 27087709)
3. Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res. 2007;31:439-44.
4. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res. 2008;78:413-21. (Pubitemid 351769775)
5. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003;93:e17-24.
6. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourao PA. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta. 2005;1740:45-53. (Pubitemid 40692697)
7. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258:6713-6. (Pubitemid 13059936)
8. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood. 2007;110:4261-7. (Pubitemid 351377790)
9. Gozzo AJ, Nunes VA, Carmona AK, Nader HB, von Dietrich CP, Silveira VL, et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Int Immunopharmacol. 2002;2:1861-5. (Pubitemid 35373927)
10. Belmiro CL, Castelo-Branco MT, Melim LM, Schanaider A, Elia C, Madi K, et al. Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem. 2009;284:11267-78.
11. Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, Artaud C, Shaaf S, et al. Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer. 2007;120:1179-91.
12. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-9. (Pubitemid 34083741)
13. Leidenfrost JE, Khan MF, Boc KP, Villa BR, Collins ET, Parks WC, et al. A model of primary atherosclerosis and post-angioplasty restenosis in mice. Am J Pathol. 2003;163:773-8. (Pubitemid 36913571)
14. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res. 1976;8:859-67.
15. Coughlin SR. Protease-activated receptors in the cardiovascular system. Cold Spring Harb Symp Quant Biol. 2002;67:197-208. (Pubitemid 36775512)
16. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52. (Pubitemid 29035956)
17. He L, Giri TK, Vicente CP, Tollefsen DM. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood. 2008;111:4118-25.
18. Hasenstab D, Lea H, Hart CE, Lok S, Clowes AW. Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. Circulation. 2000;101:2651-7. (Pubitemid 30350646)
19. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333-42. (Pubitemid 28007463)
20. Li G, Sanders JM, Phan ET, Ley K, Sarembock IJ. Arterial macrophages and regenerating endothelial cells express P-selectin in atherosclerosis-prone apolipoprotein E-deficient mice. Am J Pathol. 2005;167:1511-8. (Pubitemid 41713306)